Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma NEW YORK and LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company

A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye. Elevated VEGF is associated with choroidal neovascularisation (CNV), the cause of wet AMD.

Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets. Votucalis captures histamine and thereby has the unique potential to prevent activation of all four histamine